Prognostic factors in follicular lymphoma: A single institution study

Oncology Reports

Volumn 20, Issue 1, 2008, Pages 185-193

  Jacobi, Nicole ^a   Rogers, T B ^b   Peterson, B A ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Follicular lymphoma

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HEMOGLOBIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

ADULT; AGE; AGED; ANEMIA; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE DURATION; FEMALE; FOLLICULAR LYMPHOMA; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; THERAPY DELAY; TIME; UNIVARIATE ANALYSIS; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HEMOGLOBINS; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 49849089356     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.20.1.185     Document Type: Article

References (46)

1. Jones SE, Rosenberg SA, Kaplan HS, Kadin ME and Dorfman RF: Non-Hodgkin's lymphoma: II. Single agent chemotherapy. Cancer 30: 31-38, 1972.
2. Solal-Celigny P, Brice P, Brousse N, Caspard H, Bastion Y, Haioun C, Bosly A, Tilly H, Bordessoule D, Sebban C, Harousseau JL, Morel P, Dupas B, Plassart F, Vasile N, Fort N and Leporrier M: Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe D'Etude des Lymphomes de l'Adulte. J Clin Oncol 14: 514-519, 1996.
3. Gupta R and Lister T: Curent management of follicular lymphoma. Current Opin Oncol 8: 360-365, 1996.
4. Lister TA, Cullen MH, Beard ME, Brearley RL, Whitehouse JM, Wrigley PF, Stansfeld AG, Sutcliffe SB, Malpas JA and Crowther D: Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. Br Med J 1: 533-537, 1978.
5. Glick JH, Barnes JM, Ezdinli EZ, et al: Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 58: 920-925, 1981.
6. Dan BW, Dahlberg S, Nathwani BN, et al: Long term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11: 644-651, 1993.
7. Peterson BA: Current treatment of follicular low-grade lymphomas. Semin Oncol 26 (Suppl. 14): S2-S11, 1999.
8. Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield CD, Nissen NI, Hurd DD, Henderson ES, Sartiano GP, Johnson JL, Holland JF and Gottlieb AJ: Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 21: 5-15, 2003.
9. Rodriguez I, McLaughlin P, Hagemeister FB, Fayad L, Rodriguez MA, Santiago M, Hess M, Romaguera J and Cabanillas F: Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 93: 2202-2207, 1999.
10. Zinzani PL, Pulsoni A, Perroti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, Tucci A, Molinari AL, Gobbi M, Fallini B, Fattori PP, Ciccone F, Allinari L, Martelli M, Pileri S, Tura S and Baccarani M: Fludarabine plus Mitoxantrone with and without Rituximab versus CHOP with and without Rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 22: 2654-2661, 2004.
11. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D and Cerny T: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103: 4416-4423, 2004.
12. Ghobrial I and Witzig T: Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma. Oncology 18: 623-630, 2004.
13. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, Straetmans N, Tilly H, Tabah I and Solal-Celigny P: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15: 1110-1117, 1997.
14. Smalley RV, Andersen JW, Hawkins MJ, Bhide V, O'Connell MJ, Oken MM and Borden EC: Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 19: 1336-1341, 1992.
15. Aviles A, Duque G, Talavera A and Guzman R: Interferon alpha 2b as maintenance therapy in low-grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma 20: 495-499, 1996.
16. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B and Levy R: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 89: 3129-3135, 1997.
17. Veelken H: Active immunotherapy in follicular lymphoma. Semin Cancer Biol 13: 241-247, 2003.
18. Chanan-Khan A and Czuczman MS: Bcl-2 antisense therapy in B-cell malignant proliferative disorders. Curr Treat Options Oncol 5: 261-267, 2004.
19. MacManus MP and Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14: 1282-1290, 1996.
20. Aviles A, Delgado S, Fernandez R, Talavera A, Neri N and Huerta-Guzman J: Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. Eur J Haematol 68: 144-149, 2002.
21. Van Besien K, Loberiza FR Jr, Bajorunaite R, Armitage JO, Bashey A, Burns LJ, Freytes CO, Gibson J, Horowitz MM, Inwards DJ, Marks DI, Martino R, Maziarz RT, Molina A, Pavlovsky S, Pecora AL, Schouten HC, Shea TC, Lazarus HM, Rizzo JD and Vose JM: Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102: 3521-3529, 2003.
22. Jones SE: Follicular lymphoma - do no harm. Cancer Treat Rep 70: 1055-1058, 1986.
23. Horning SJ and Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311: 1471-1475, 1984.
24. Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES and DeVita VT Jr: The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 25 (Suppl. 2): S11-S16, 1988.
25. Advani R, Rosenberg SA and Horning SJ: Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 22: 1454-1459, 2004.
26. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329: 987-994, 1993.
27. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89: 3909-3918, 1997.
28. Lopez-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E and Rozman C: Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 12: 1343-1348, 1994.
29. Bastion Y and Coiffier B: Is the International Prognostic Index for aggressive lymphoma patients useful for follicular lymphoma patients? J Clin Oncol 12: 1340-1342, 1994.
30. Aviles A: The International Index is not useful in the classification of low-grade lymphoma. J Clin Oncol 12: 2766-2768, 1994.
31. Aviles A, Neri N, Cuadra I, Alvarado I, Fernandez R, Calva A and Huerta-Guzman J: Lack of prognostic factors in follicular lymphoma. Leuk Lymphoma 44: 143-147, 2003.
32. Foussard C, Desablens B, Sensebe L, Francois S, Milpied N, Deconinck E, Delwail V, Dugay J, Lamy T, Ghandour C, Le Mevel A, Maisonneuve H, Casassus P and Colombat P: Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France. Ann Oncol 8 (Suppl. 1): S49-S52, 1997.
33. Hermans J, Krol AD, van Groningen K, Kluin PM, Kluin-Nelemans JC, Kramer MH, Noordijk EM, Ong F and Wijermans PW: International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 86: 1460-1463, 1995.
34. Bastion Y, Berger F, Bryon PA, Felman P, Ffrench M and Coiffier B: Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 2 (Suppl. 2): S123-S129, 1991.
35. Coiffier B, Gisselbrecht C, Vose JM, Tilly H, Herbrecht R, Bosly A and Armitage JO: Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol 9: 211-219, 1991.
36. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clo V, Bellesi G, Magagnoli M, Liberati M, Boccomini C, Niscola P, Pavone V, Cuneo A, Santini G, Brugiatelli M, Baldini L, Rigacci L and Resegotti L: Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 95: 783-789, 2000.
37. Perea G, Altes A, Montoto S, Lopez-Guillermo A, Bosch F, Jimenez M, Esteve J, Domingo E, Ribera JM, Pedro C, Martino R, Briones J, Sureda A, Brunet S, Sierra J and Montserrat E: International and Italian prognostic indices in follicular lymphoma. Haematologica 88: 700-704, 2003.
38. Maartense E, Le Cessie S, Kluin-Nelemans HC, Kluin PM, Snijder S, Wijermans PW and Noordijk EM: Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry. Ann Oncol 13: 1275-1284, 2002.
39. Leonard RC, Hayward RL, Prescott RJ and Wang JX: The identification of discrete prognostic groups in low-grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol 2: 655-662, 1991.
40. Romaguera JE, McLaughlin P, North L, Dixon D, Silvermintz KB, Garnsey LA, Velasquez WS, Hagemeister FB and Cabanillas F: Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 9: 762-769, 1991.
41. Cameron DA, Leonard RC, Mao JH and Prescott RJ: Identification of prognostic groups in follicular lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Leuk Lymphoma 10: 89-99, 1993.
42. Rodriguez J, Cabanillas F, McLaughlin P, Swan F, Rodriguez M, Hagemeister F and Romaguera J: A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol 3: 711-717, 1992.
43. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, Le Blanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E and Montserrat E: Follicular lymphoma international prognostic index. Blood 104: 1258-1265, 2004.
44. Björck E, Ek S, Landgren O, et al: High expression of cyclin B1 predicts a favorable outcome of patients with follicular lymphoma. Blood 105: 2908-2915, 2004.
45. Dave SS, Wright G, Tan B, et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351: 2159-2169, 2004.
46. Rohatiner AZ, Gregory WM, Peterson B, et al: Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23: 2215-2223, 2005.